Max Herrmann

Herrmann, Max

 

Born May 14, 1865, in Berlin; died Nov. 17, 1942, in the Terezin concentration camp. German historian of literature and the theater. Founder of German scientific study of the theater.

Herrmann began teaching at the University of Berlin in 1891 with a course on the history of literature. From 1901 he concentrated on the history and theory of the theater. He was the author of Research on the History of the German Theater of the Middle Ages and the Renaissance, published in 1914. He used extensive documentary material and endeavored to recreate plays of the past. However, his idealistic worldview made him view the theatrical productions of the past as isolated from general historical and literary developments. In 1923 the Institute of Theater History was established at the University of Berlin on his initiative. After the fascist coup d’etat in Germany, he was removed from his post of professor and confined in a concentration camp where he died.

WORKS

Albrecht von Byb und die Frühzeit des Deutschen Humanismus in Nürnberg. Berlin, 1893.
Die Reception des Humanismus in Nürnberg. Berlin, 1898.
Jahrmarktsfest zu Plundersweilern: Entsehungs- und Bühnengeschichte. Berlin, 1900.
Forschungen zur deutschen Theatergeschichte des Mittelalters und der Renaissance, vols. 1-2. Dresden, 1955.
Die Bühnenidee des Hans Sachs. Berlin, 1924.

REFERENCE

Gvozdev, A. A. Iz istorii teatra i dramy. Petrograd, 1923.
References in periodicals archive ?
Biotechnology company Silence Therapeutics plc (LSE:SLN) announced today that it has appointed Max Herrmann as chief financial officer and company secretary, effective from 4 May 2010.
'They're (S&N) paying a low price, but they're taking on the risk of some of Centerpulse's liabilities,' said Max Herrmann, an industry analyst at ING Financial Markets.
Max Herrmann, analyst at ING Charterhouse, said the drug would help sales of the Avandia franchise reach pounds 1.5bn by 2006.''
ING Charterhouse analyst Max Herrmann analyst said it was unlikely that Bristol-Myers would be able to solve Glaxo's pipeline problems.
Max Herrmann, analyst at ING Charterhouse, believed it was unlikely that Bristol-Myers would be able to solve Glaxo's pipeline problems.
Housebroker Max Herrmann at ING Barings said: 'Dechra is just a distributor and has no influence over vet's pricing policy.
Max Herrmann, pharmaceutical analyst at ING Charterhouse, said, "It's partly Crestor but given the speed the shares came off it's probably also profit taking.